Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

BACKGROUND: A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall survival (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Tomita, Yoshihiko, Uemura, Hirotsugu, Oya, Mototsugu, Shinohara, Nobuo, Habuchi, Tomonori, Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, Bair, Angel H., Rini, Brian I.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6322336/
https://ncbi.nlm.nih.gov/pubmed/30616534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-5224-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados